Sponsored Budget

POM Antwerp (50%), EFRO (40%), Hermes Fund (10%)

Project Period

The anicells’ manufacturing site is operational since Q4 2019 in compliance with most recent European regulations for the manufacturing of advanced therapy medicinal products (ATMP) from both animal and human origin. anicells’ facilities have multiple sterile cell-processing cleanrooms with classification B and C, including hi-tech closed-system cell-purification devices as well as a QC lab.